<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103778</url>
  </required_header>
  <id_info>
    <org_study_id>X05320</org_study_id>
    <secondary_id>1001010854</secondary_id>
    <nct_id>NCT01103778</nct_id>
  </id_info>
  <brief_title>Pilot Study of Velcade® in IgA Nephropathy</brief_title>
  <official_title>Velcade Therapy for Severe IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to
      induce complete or partial remission in patients with severe IgA nephropathy.

      The secondary objectives are to assess clinical outcomes relating to safety and efficacy,
      such as infection, malignancy, preservation of renal function, partial responders, relapse
      rate, and to study mechanistic assays to predict remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This exploratory single center, open-label, single treatment group assignment, safety and
      efficacy study will enroll 15 patients with severe IgA nephropathy. Subjects will receive 1
      cycle of Velcade® to induce clinical remission. Follow-up visits will occur monthly for a
      year.

      For this pilot study, the proportion of patients with clinical remission or partial response
      will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 17, 2017</completion_date>
  <primary_completion_date type="Actual">April 17, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Quantification of urinary protein will be made after treatment by measuring 24 hr urine protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Complete Remission, Partial Response, or no Response.</measure>
    <time_frame>1 year</time_frame>
    <description>Complete remission was defined as daily proteinuria of less than 300mg measured by 24 hr urine collection.
Partial response was defined as any reduction in daily proteinuria from baseline as measure by 24 hr urine collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>Preservation of renal function will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Lab Values or Infections Related to Exposure to Study Medication.</measure>
    <time_frame>1 year</time_frame>
    <description>Complete blood count will be checked at regular intervals to monitor for anemia; liver panel; serum immunoglobulin profile will also be followed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Velcade® therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with greater than 1gm of proteinuria per day will receive Velcade®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib (Velcade®)</intervention_name>
    <description>Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).</description>
    <arm_group_label>Velcade® therapy</arm_group_label>
    <other_name>Velcade®</other_name>
    <other_name>Bortezomib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age or older.

          2. Must have IgA nephropathy documented by kidney biopsy.

          3. Must have greater than 1gm of proteinuria a day.

          4. Must be on a stable dose of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or
             Angiotensin Receptor Blocking agent (ARB) for at least 4 weeks prior to screening.

        Exclusion Criteria:

          1. Low platelet count and neutrophil count within certain limits defined for enrollment.

          2. Underlying peripheral neuropathy.

          3. Having cardiac problems, such as myocardial infarction, heart failure, uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities.

          4. Allergic to VELCADE®, boron or mannitol.

          5. Female subjects who are pregnant or breast-feeding.

          6. Recent use of investigational drug within 14 days before enrollment.

          7. Having serious medical conditions and infections (including HIV,or hepatitis B or C)
             or psychiatric illness likely to interfere with participation in the study.

          8. Diagnosed or treated for cancer within 3 years of participation in the study, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, and in situ malignancy, or low-risk prostate cancer after curative therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choli Hartono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rogosin.org</url>
    <description>The Rogosin Institute</description>
  </link>
  <results_reference>
    <citation>Hartono C, Chung M, Perlman AS, Chevalier JM, Serur D, Seshan SV, Muthukumar T. Bortezomib for Reduction of Proteinuria in IgA Nephropathy. Kidney Int Rep. 2018 Mar 11;3(4):861-866. doi: 10.1016/j.ekir.2018.03.001. eCollection 2018 Jul.</citation>
    <PMID>29988921</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <results_first_submitted>September 21, 2018</results_first_submitted>
  <results_first_submitted_qc>September 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2018</results_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>IgA nephropathy</keyword>
  <keyword>Velcade®</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Proteasome inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT01103778/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Velcade Arm</title>
          <description>Single treatment arm:
Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Proteinuria improved prior to enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with greater than 1gm of proteinuria per day will receive Velcade®.</population>
      <group_list>
        <group group_id="B1">
          <title>Velcade® Therapy</title>
          <description>Bortezomib (Velcade®): Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proteinuria</title>
        <description>Quantification of urinary protein will be made after treatment by measuring 24 hr urine protein.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>1 participant was lost to followup.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade® Therapy</title>
            <description>Patients with greater than 1gm of proteinuria per day will receive Velcade®.
Bortezomib (Velcade®): Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Proteinuria</title>
          <description>Quantification of urinary protein will be made after treatment by measuring 24 hr urine protein.</description>
          <population>1 participant was lost to followup.</population>
          <units>grams per 24 hrs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="1.17" upper_limit="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="0.10" upper_limit="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Remission, Partial Response, or no Response.</title>
        <description>Complete remission was defined as daily proteinuria of less than 300mg measured by 24 hr urine collection.
Partial response was defined as any reduction in daily proteinuria from baseline as measure by 24 hr urine collection.</description>
        <time_frame>1 year</time_frame>
        <population>1 participant was lost to followup.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade Arm</title>
            <description>Single treatment arm:
Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Remission, Partial Response, or no Response.</title>
          <description>Complete remission was defined as daily proteinuria of less than 300mg measured by 24 hr urine collection.
Partial response was defined as any reduction in daily proteinuria from baseline as measure by 24 hr urine collection.</description>
          <population>1 participant was lost to followup.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine</title>
        <description>Preservation of renal function will be assessed.</description>
        <time_frame>Baseline and 1 year</time_frame>
        <population>1 participant lost to followup.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade Arm</title>
            <description>Single treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <description>Preservation of renal function will be assessed.</description>
          <population>1 participant lost to followup.</population>
          <units>milligram per deciliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="0.54" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" lower_limit="0.52" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Lab Values or Infections Related to Exposure to Study Medication.</title>
        <description>Complete blood count will be checked at regular intervals to monitor for anemia; liver panel; serum immunoglobulin profile will also be followed.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Velcade Arm</title>
            <description>Single treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Lab Values or Infections Related to Exposure to Study Medication.</title>
          <description>Complete blood count will be checked at regular intervals to monitor for anemia; liver panel; serum immunoglobulin profile will also be followed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Velcade® Therapy</title>
          <description>Patients with greater than 1gm of proteinuria per day will receive Velcade®.
Bortezomib (Velcade®): Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild reversible decline platelet count</sub_title>
                <description>Related to exposure to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our pilot study has several significant limitations, including small sample size, no control group, and nonrandomization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Choli Hartono</name_or_title>
      <organization>Rogosin Institute</organization>
      <phone>212-746-1578</phone>
      <email>chh2001@nyp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

